ERYTECH to Present at Morgan Stanley Global Healthcare Conference
Conference Details:
- Conference:
Morgan Stanley Global Healthcare Conference - Date:
Wednesday, September 13th, 2017 - Time:
2:10 p.m. EST
Investors attending the conference who would like to schedule a
one-on-one meeting with management may do so by contacting their
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
Founded in
The company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multiagent chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), but side effects limit treatment, especially in adults and patients with weak performance status. With its improved safety profile, eryaspase aims to provide L-asparaginase to patients who cannot tolerate current non-encapsulated asparaginases.
Eryaspase achieved positive efficacy and safety results in a Phase 2
study in elderly patients with ALL, and a Phase 2/3 study in children
and adults with relapsed or refractory ALL. ERYTECH believes that the
positive results of its Phase 2b clinical study in second-line
metastatic pancreatic cancer are significant indicators of eryaspase as
a potential treatment approach in solid tumors. ERYTECH also has an
ongoing Phase 1 clinical study of eryaspase in
ERYTECH produces eryaspase at its own GMP-approved and operational
manufacturing site in
In addition to eryaspase, ERYTECH is developing two other product candidates, erymethionase and eryminase, that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on
Forward-looking information
This press release contains forward-looking statements, forecasts and
estimates with respect to the clinical development plans, business and
regulatory strategy, and anticipated future performance of ERYTECH and
of the market in which it operates. Certain of these statements,
forecasts and estimates can be recognized by the use of words such as,
without limitation, “believes”, “anticipates”, “expects”, “intends”,
“plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar
expressions. They include all matters that are not historical facts.
Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties
and other factors, which were deemed reasonable when made but may or may
not prove to be correct. Actual events are difficult to predict and may
depend upon factors that are beyond ERYTECH's control. There can be no
guarantees with respect to pipeline product candidates that the
candidates will receive the necessary regulatory approvals or that they
will prove to be commercially successful. Therefore, actual results may
turn out to be materially different from the anticipated future results,
performance or achievements expressed or implied by such statements,
forecasts and estimates. Documents filed by
View source version on businesswire.com: http://www.businesswire.com/news/home/20170911006288/en/
Source:
ERYTECH
Naomi Eichenbaum, + 1 917-312-5151
Director
of Investor Relations
naomi.eichenbaum@erytech.com
or
The
Ruth Group
Media Relations
Kirsten Thomas, +1
508-280-6592
kthomas@theruthgroup.com
or
NewCap
Julien
Perez, +33 1 44 71 98 52
Investor Relations
or
Nicolas
Merigeau, +33 1 44 71 98 52
Media Relations
erytech@newcap.eu